Tag - ZURA

Executive Moves

Drs. Mark Eisner and Ajay Nirula join Zura Bio’s BOD

Zura Bio (NASDAQ: ZURA) has announced the appointments of Mark Eisner, MD, PhD, and Ajay Nirula, MD, PhD, to its board of directors (BOD), effective February 21, 2026. Neil Graham, MBBS, MD, MPH, stepped down from the...

February 23, 2026

Executive Moves

Zura names Dr. Sandeep Kulkarni as CEO

Zura Bio (NASDAQ: ZURA) has appointed Sandeep Kulkarni, MD, as chief executive officer (CEO), effective today. Dr. Kulkarni will continue to serve as a director of Zura. He succeeds Kim Davis, JD, who has served as...

January 21, 2026

Developments

Zura Bio launches global Phase 2 study of tibulizumab in HS

Zura Bio (NASDAQ:ZURA) announced that it has launched a global Phase 2 study—TibuSHIELD—to evaluate tibulizumab in 180 adults with moderate to severe hidradenitis suppurativa (HS) across Canada, the U.S. and Europe...

May 21, 2025

Tag - ZURA

Drs. Mark Eisner and Ajay Nirula join Zura Bio’s BOD

Zura names Dr. Sandeep Kulkarni as CEO

Zura Bio launches global Phase 2 study of tibulizumab in HS

Subscribe